illumisoft

Revolutionizing indoor health through *light*

INVESTOR PRESENTATION

TSX-V : UVC OTCQB : FUVCF

October 2026

LEGAL NOTICE

illumisoft

Important disclosures.

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). All statements other than statements of historical fact are forward-looking, including, without limitation, statements regarding product development plans, regulatory pathways, market opportunity, manufacturing capacity, partnership prospects, Far-UVC commercialization timelines, and the company's capital structure.

Forward-looking statements are based on assumptions and estimates management believes reasonable as of the date hereof. Actual results may differ materially due to risks including, but not limited to, regulatory delays, product development risk, competitive pressure, supply-chain disruption, customer adoption rates, capital market conditions, and the risks set forth in the company's continuous disclosure record on SEDAR+. The company undertakes no obligation to update forward-looking statements except as required by law.

NON-IFRS MEASURES

Certain financial measures referenced herein, including target gross margin, target unit pricing, serviceable addressable market, and bottom-up revenue path, are not recognised under International Financial Reporting Standards. Such measures do not have standardised meanings under IFRS and may not be comparable to similarly titled measures presented by other issuers.

INDUSTRY AND MARKET DATA

Market data, statistics, and forecasts cited herein are derived from third-party sources, internal estimates, and management assumptions. While the company believes such information to be reliable, it has not been independently verified. Statements regarding market size, penetration rates, competitive positioning, and the performance of competing products reflect management's views and may not be representative of actual outcomes. Independent third-party validation referenced, including the University of Leeds aerobiology study, reflects testing conducted under specified laboratory conditions; real-world performance may vary.

NO OFFER OR SOLICITATION

This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security in any jurisdiction in which such offer or solicitation would be unlawful. Any offer or sale of securities will be made only by means of a prospectus, offering memorandum, or subscription agreement filed or delivered in accordance with applicable securities laws.

U.S. SECURITIES ACT RESTRICTIONS AND CONFIDENTIALITY

The securities of the company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S) absent registration or an applicable exemption. This presentation is strictly confidential; reproduction or distribution is prohibited without prior written consent.

THE PROBLEM

illumisoft

We solved fire. We solved water. We never solved air.


Healthcare-acquired infections in Canada, every year.

473,590

Infections caught in Canadian hospitals.

33,151

Deaths linked to those infections.



C$19.85B

Lost hospital-bed capacity


C$9.47B

Treatment costs

WHAT EACH AVOIDED INFECTION IS WORTH

~$20,000**

Treatment and bed capacity a hospital gets back.



Source: CHAIR (Coalition for Community and Healthcare Acquired Infection Reduction), The National Economic Impact of Healthcare-Acquired Infections in Canada. **$20,000 per infection is an illustrative estimate from published literature; actual value varies by infection type and setting.

ANTIBIOTIC RESISTANCE

illumisoft

When antibiotics stop working, prevention has to.

1.27M

Deaths directly caused by resistant bacterial infections in 2019.

39M

Deaths projected from resistant infections, 2025 to 2050.

136M


Healthcare-associated resistant infections every year.

HOW ILLUMISOFT HELPS


UV-C inactivates bacteria by damaging their DNA. Antibiotic resistance does not protect against it.

Every infection prevented is one that never needs an antibiotic, resistant or not.

UP TO, IN INDEPENDENT CHAMBER TESTING (LEEDS)



P. aeruginosa



S. aureus

Sources: GRAM, The Lancet (2022, 2024); WHO. Leeds results are aerobiology chamber testing of species behind many resistant hospital infections.

WHY NOW

illumisoft

Standards are tightening. Canada moved first.

Standards, procurement, liability and preparedness, 2024 to 2026.

1

Indoor air is a health crisis

Indoor transmission drives the burden, and clean-air expectations have moved.

2

Standards are tightening

WHO and CDC raised clean-air targets. ASHRAE 241 sets new clean-airflow rules.

3

Canada moved first on UV

CSA Z8000:24 adds annexes on supplemental disinfection technologies, and CSA Z317.12:25 addresses UV in healthcare facilities, ahead of global adoption.

4

Liability drives urgency

Procurement is converting from awareness into signed contracts.

INDEPENDENT VIEW

“

Far-UVC represents one of the highest-leverage funding opportunities in airborne disease and pandemic prevention that we are aware of.

Blueprint Biosecurity / Blueprint for Far-UVC, 2025

10:1

ROI cited for ASHRAE 241 clean-air compliance analyses.

30 to 290x

Blueprint Biosecurity estimates of benefit-cost for Far-UVC in public indoor spaces.

ILLUMISOFT'S SOLUTION

Proven today. Coming next. Earning now.




SaniLume

COMMERCIAL GUV

ACTIVE

201 to 1,994 eACH

Every other device tested at Leeds: 17.1 or less.



SaniLux

FAR-UVC IN DEVELOPMENT

COMING SOON

216 nm

Designed for 10x far-UVC per dollar of excimer (target).



ECOWing

COMMERCIAL LIGHTING

REVENUE PRODUCING

34 of 50

Top DLC products in its category.

1

$248B+

Market opportunity

2

20

Granted U.S. patents

3

Up to 99.7%

Independent chamber testing

4

10+

Verticals served

TSX-V : UVC OTCQB : FUVCF

THE PEOPLE BEHIND IT

illumisoft

Backed by people who built at global scale.



Chris Anderson

TED / INVESTOR

Took TED Talks to a worldwide audience.

TED



Rob Reid

RHAPSODY / ADVISOR

Technology investor and Illumisoft strategic advisor.



Dr. Jonathan Ketcham

STRATEGIC ADVISOR

Former White House Chief Healthcare Economist.



Bill Weber

CHIEF STRATEGY OFFICER

Former New Growth Ventures leader at 3M.

3M

Capgemini

PRODUCT PARTNER

EUR 22.5B group, engineering SaniLux.

19.43%

Held through Resilience Reserve. Their own capital is in the company.

Adoption economics, growth strategy and product engineering. White House healthcare economics, 3M new-venture strategy, and SaniLux engineering at Capgemini scale.

SANILUME / AVAILABLE TODAY

illumisoft

The best UV device tested in the Leeds chamber.

254 nm upper-room UV. It treats the air while the room stays in use.

AIR CHANGES PER HOUR, INDEPENDENT CHAMBER TESTING

201 to 1,994 eACH

Every other device tested in the same chamber: 0.003 to 17.1.





Up to 99.7%

P. aeruginosa reduction

Reduction of test organisms in independent chamber testing, University of Leeds.

Registered

Health Canada

PMRA Reg. No. 35270 as a commercial indoor UVC air sanitizer.

Shipping

Active revenue line

Hospital program budgeted at 1,500 units.*

*Budgeted units, subject to finalization of contracts by CHAIR.

TSX-V : UVC OTCQB : FUVCF

CHAIR HOSPITAL RESEARCH PROGRAM

illumisoft

CHAIR is taking SaniLume into Canadian hospitals.

A CHAIR-led research program to evaluate SaniLume, with facility-wide installations planned in Manitoba and British Columbia.

3

health organizations

Non-binding LOIs with CHAIR for facility-wide installations

13

linked studies

Airborne pathogens, surface contamination, respiratory transmission

Nov 2026

studies targeted to begin

Subject to funding

Manitoba

Shared Health and Health Sciences Centre Winnipeg

British Columbia

Provincial Health Services Authority

University of Waterloo

First two studies: bioaerosol chamber and airflow modelling

> *Treating the air while patients and staff are in the room is the next step.*

Barry Hunt Co-Founder and Executive Director, CHAIR

Units, pricing and terms are not yet finalized. Illumisoft is not a party to the hospital LOIs and does not control program timing.

SANILUX / DESIGN TARGETS


illumisoft

A new source. A broader ambition.

216 nm

Proprietary nanoengineered Far-UVC.
Core IP owned by Illumisoft.

IN DEVELOPMENT / OWNED IP



10x

Far-UVC per dollar, target

US$350 module, 1 W target, against the best excimer fixture on the market.

1 W

Far-UVC output, design target

Today's filtered excimer modules deliver about 100 mW.

0 to 100%

Output control, in nanoseconds

Full power when the room is empty, exposure-limit output the moment people walk in.

No filter. No gas. No licence.

Solid-state architecture

The spectrum is set by the material, not a plasma and a bandpass filter.

Always on: designed to run continuously at the exposure limit, where excimer fixtures run about 7% of the day. **10,000 h** design life at full output.

illumisoft

From breakthrough science to products built for real life.

illumisoft | Capgemini

Delivered through frog and Synapse, part of Capgemini.

EUR 22.5B

Global revenue

Full year 2025

417,600

People worldwide

As at 30 June 2026

50+

Countries

Global operations

1 Design for use



Industrial design and product forms for real environments.

2 Engineer to build



Engineering architecture, supply chain and manufacturing.

3 Prepare to launch



Prototypes, pilot readiness and launch planning.

ECOWING / THE COMMERCIAL FOUNDATION

illumisoft

34 of the top 50. In one portfolio.

167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa.
The revenue base and the warm channel into both UV platforms.

REVENUE PRODUCING



167 lm/W	60 to 75%	5 min	50,000 h	17	40 to 55%
Peak efficacy	Energy savings	Install time	Lifespan	Patents	Gross margin

TRUSTED ACROSS GOVERNMENT, HEALTHCARE AND REAL ESTATE

Health Canada · NRC National Research / CAN · National Defence / Canada · Queensway Carleton Hospital · CSA Group Z317.12:25 · IES Award 2023

QuadReal · BGO BentallGreenOak $83B AUM · Triovest · BGIS · DLC DesignLights · Blueprint Biosecurity

TSX-V : UVC OTCQB : FUVCF

THE OPPORTUNITY

illumisoft

Hospitals first. Then every room people share.



$9.7B

SaniLume

Hospital serviceable addressable market.

230K x 12 units. Source cites $96M at 1%.




~$8B

ECOWing

North American LED retrofit market.

Top five players hold about 20%.



$5.25B

SaniLux

Phase 1: hospitals and aviation.

Phase 2 schools and commercial, $35B+.

Context: $248B global infection-control market in 2024, $473B by 2034 at a 6.7% CAGR. UV penetration 5 to 30%; North America 40 to 49% share.

PATH TO SCALE

ACTIVE

Canada first

10 to 15K

Units/year capacity reported for Ottawa.

QUEUED

International expansion

50K

Units/year capacity target for the next phase.

SCALE

SaniLux commercialization

216 nm

Own the Far-UVC platform and sell it directly.

Revenue lines: ECOWing lighting sales (40 to 55% gross margin reported), SaniLume devices and deployments, SaniLux direct sales once development completes.

WHAT HAPPENS NEXT

illumisoft

The next milestones are already in motion.

Company targets and stated next steps. Timing depends on partners and approvals.

TODAY

IN PROGRESS

1

Convert the program

CHAIR sign-off, funder deposit and on-site audit move 1,500 budgeted units* toward orders.

IN PROGRESS

2

Engineer SaniLux

Design, engineering and pilot readiness with Capgemini, through frog and Synapse.

NEXT

3

Open the US channel

Sales and channel expansion across Canada and the US, 30% of proceeds.

Q1 2027 TARGET

4

First SaniLux unit

Validation units in build. Pilot Q3 to Q4 2026, commercial target Q1 2027.

Each step is a public, reportable event.

Today's indicative market capitalization, about C$51M in early September 2026, was set before any of them.



R-Zero: estimated 2023 post-money valuation in a private round, US$526.9M at 16 September 2026 FX. Illumisoft: listed and trading.

*Budgeted units, subject to finalization of contracts by CHAIR.

Science, commercialization and adoption.



Ehsan Agahi

CHIEF EXECUTIVE OFFICER

Zephyr Venture Partners. Biotech and life-sciences M&A.



Bill Weber

CHIEF STRATEGY OFFICER

Former New Growth Ventures leader at 3M. Ex-General Counsel, Cbeyond.



Dr. Michael Johnson

CHIEF TECHNOLOGY OFFICER

Physics PhD, ASU. Former Motorola semiconductor. Architect of SaniLux.



Ali Pickett

CHIEF FINANCIAL OFFICER

15+ yrs financial leadership. Managed $8B+ in assets. TSX-V experience.

BOARD AND ADVISORS



Brett Nicholds

STRATEGIC ADVISOR

Led Illumisoft from precommercialization to national distribution.



Cameron Groome

DIRECTOR

CEO Microbix Biosystems (TSX). Advised Global Affairs Canada.



Ryan Adam

DIRECTOR

Wellington DuPont. Former PMO Western Canada and Natural Resources.

CAPITAL STRUCTURE

illumisoft

Capitalization and capital deployment.

SHARES OUTSTANDING


Issued common shares	46,173,389
Options	3,540,000
Finder warrants	425,390

FULLY DILUTED

50,138,779

Per the fully diluted table in the 21 April 2026 qualifying transaction closing release.

USE OF PROCEEDS



- **~35%** Manufacturing and inventory scale
- **~30%** Sales and channel expansion, CA and US
- **~20%** SaniLux R&D and prototype completion
- **~15%** Working capital and G&A

TSX-V : UVC OTCQB : FUVCF

INVESTMENT THESIS

Six reasons. Why Illumisoft.

1

Structural demand

Standards

CSA Z8000:24 and Z317.12:25 put engineered air disinfection in front of Canadian healthcare planners.

2

Validated performance

201 to 1,994 eACH

201 to 1,994 equivalent air changes per hour in independent chamber testing, versus 0.003 to 17.1 for every other device tested.

3

An unpriced option

216 nm

Solid-state Far-UVC designed for 10x far-UVC per dollar of excimer (target). Own issued patent, no licence. Not priced into the market cap.



4

Mission-aligned backers

19.43%

Held by Chris Anderson and Rob Reid through Resilience Reserve.

5

Two existential tailwinds

US$855B

Modeled annual treatment and productivity losses from resistant infections, to 2035.

6

An anchor already signed

1,500 units*

Two CHAIR hospital programs budgeted under a signed LOI, against roughly C$51M.

*Budgeted units, subject to finalization of contracts by CHAIR.

Safer air.
Better health.
Better future.

illumisoft

WEB
illumisoft.com

CONTACT
info@illumisoft.com

REGISTERED
Ottawa, Canada

LISTINGS
TSX-V : UVC / OTCQB : FUVCF